| Question 1: Extracting quantitative transport parameters from DCE-MRI acquisitions is challenging. The choice of different perfusion analysis software packages corresponded to within-subject coefficient variation for K¬trans in the range of |
| Reference: | Jaffray DA, Chung C, Coolens C, Foltz W, Keller H, Menard C, et al. Quantitative Imaging in Radiation Oncology: An Emerging Science and Clinical Service. Semin Radiat Oncol [Internet]. 2015 Oct 1 [cited 2018 Apr 10];25(4):292–304. Available from: https://www.sciencedirect.com/science/article/pii/S1053429615000557 |
| Choice A: | 28.3% - 48.8% |
| Choice B: | 48.3% - 68.8% |
| Choice C: | 68.3% - 88.8% |
| Choice D: | 38.3% - 58.8% |
| Question 2: Major impediments to broad adoption of molecular imaging include: |
| Reference: | Jeraj R, Bradshaw T, Simon i U. Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy. J Nucl Med [Internet]. 2015;56(11):1752–65. Available from: http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.114.141424 |
| Choice A: | Lack of clinical evidence, immature technology, tracer scarcity, and inadequate recommendation. |
| Choice B: | Lack of clinical evidence, immature technology, lack of reimbursement models, and inadequate recommendation. |
| Choice C: | Lack of clinical evidence, inadequate training, lack of reimbursement models, and inadequate recommendation. |
| Choice D: | Lack of clinical evidence, lack of analysis tools, tracer scarcity, and inadequate recommendation. |
| Question 3: Which of the following is the primary objective for RTOG 1106-6697 to determine when an individualized adaptive radiation treatment (RT) plan is applied by the use of an FDG-PET/CT scan acquired during the course of fractionated RT in patients with inoperable or unresectable stage III NSCLC: |
| Reference: | https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1106 |
| Choice A: | Whether tumor dose can be escalated to improve the LRPF rate at 2 years. |
| Choice B: | Whether an individualized dose escalation improves overall survival (OS). |
| Choice C: | Whether an individualized dose escalation improves progression-free survival (PFS). |
| Choice D: | Whether the rate of severe (grade 3+ CTCAE, vs. 4) radiation-induced lung toxicity (RILT) differs. |
| Question 4: Partial Response (PR) and Progressive Disease (PD) are defined by which treatment response evaluation thresholds: |
| Reference: | Eisenhouer et al 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, 45, 228-247. |
| Choice A: | PR < -30%; PD > +30% |
| Choice B: | PR < -30%; PD > +20% |
| Choice C: | PR < -20%; PD > +30% |
| Choice D: | PR < -20%; PD > +20% |
| Question 5: Repeatability is a critical quantitative imaging biomarker (QIB) quality and is defined as: |
| Reference: | Raunig et al, Quantitative Imaging Biomarkers: A Review of Statistical Methods for Technical Performance Assessment, Stat Methods Med Res 0962280214537344 |
| Choice A: | The ability of the QIB to unambiguously reflect a change in the disease state as represented by an adequate change in the QIB. |
| Choice B: | The reliability of the QIB measuring system in different conditions that might be expected (e.g. multiple sites, etc.). |
| Choice C: | The ability of the QIB to repeatedly measure the same feature under identical or near-identical conditions. |
| Question 6: The most common way to plot reproducibility is using: |
| Reference: | Raunig et al, Quantitative Imaging Biomarkers: A Review of Statistical Methods for Technical Performance Assessment, Stat Methods Med Res 0962280214537344 |
| Choice A: | Bland-Altman plots. |
| Choice B: | Kaplan-Meier plots. |
| Choice C: | Q-Q plots. |
| Choice D: | Cox proportional hazard plots. |
